| Ryzumvi (U.S.N.L.M.) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dosing | Over age 12: 1 or 2 drops in each dilated eye. Age 3 to 11: 1 drop in each dilated eye. |
||||||||||||||||||
| Chem Specs | phentolamine 0.75% ophthalmic solution | ||||||||||||||||||
| Quantities | 30 single use vials per box (8 drops / vial)
| Cost |
$295.00 + cold shipping fee |
Class |
relatively non-selective alpha-1 and alpha-2 adrenergic antagonist |
Action |
Reversibly binds to alpha-1 receptors of the iris dilator muscle |
Usage |
Indicated for the reversal of pharmacologically-induced mydriasis of adrenergic |
agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.
| Not recommended when active ocular inflammation (e.g. iritis) is present |
because adhesions (synechiae) may form between the iris and the lens. Contraindications |
None |
Pediatric use |
Safety and efficacy not established in pediatric patients below the age of 3.
|
Pregnancy |
There are no available data with Ryzumvi administration in pregnant women to inform |
a drug-associated risk. Skeletal immaturity in rats at 24x the normal human dose.
| Store refrigerated at 2°c to 8°C (36°F to 46°F). May be held at 68°F to 77°F for |
14 days after opening. Remove contact lenses prior to use; reinsert 10 minutes following administration. |